A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback